Fig. 3. The peripheral immune profile at landmark associates with the development of recurrence after therapy.

The peripheral immune profile at landmark was compared between patients who developed a recurrence (R) and those that did not (no R). Frequency of immune subsets at landmark that associate with recurrence in patients treated with (A) nivolumab, capecitabine, or nivolumab + capecitabine (n=27 with no R, n=15 with R), (B) nivolumab (n=7 with no R, n=8 with R), (C) capecitabine (n=9 with no R, n=5 with R), and (D) nivolumab plus capecitabine (n=11 with no R, n=2 with R). Differences in 10 classic peripheral blood mononuclear (PBMC) cell types and 148 refined subsets reflective of maturation and function were analyzed. Notable subsets with significant differences are displayed and include those with p < 0.05 (calculated by a two tailed Mann-Whitney test), and difference in medians > 0.05 of PBMCs. No adjustments were performed for multiple comparisons.

NK/NKT, natural killer T cells; PD-1, programmed cell death protein 1; Treg, regulatory T cell; HLA-DR, Human Leukocyte Antigen – DR isotype; ICOS, inducible T cell co-stimulator; PBMC, peripheral blood mononuclear cells. Source data are provided as a source data file.